CP-4200 is a novel LVT derivative of azacytidine, which pre-dominantly acts as a modifier of gene expression (epigenetic modulator).
Epigenetic modulators are intended to restore the normal function of genes that control how cells develop and grow in the human body at doses with low cytotoxic activity. Vidaza®(azacitidine) is currently approved in the US for all forms of myelodysplastic syndromes (MDS), while in the EU it is approved for the more severe forms of MDS as well as for certain forms of acute myeloid leukemia (AML).
CP-4200 is in preclinical development.
